DiscoveRx and BioFocus Announce a Co-Marketing Agreement for GPCR Screening

FREMONT, Calif.--(Business Wire)--
DiscoveRx Corp. and BioFocus® announced today that they have signed a
co-marketing agreement that allows BioFocus to perform screening on behalf of
BioFocus` customers using DiscoveRx PathHunter ß-Arrestin GPCR screening assay,
HitHunter cAMP assays and associated cell lines.

DiscoveRx has an industry leading portfolio of over 300 non-force coupled GPCR
cell lines utilizing its award winning PathHunter ß-Arrestin GPCR platform as
well as HitHunter cAMP detection. These validated cell lines and associated
detection platform have been used in numerous drug discovery campaigns for
de-orphanization and identifying novel hits.

"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance
our assay development and screening platform," said Chris Newton, SVP BioFocus.
"Our customers will gain advantage of our expertise coupled with the unique and
complete GPCR portfolio offered by DiscoveRx."

"We are pleased that BioFocus and DiscoveRx have forged a partnership as both
parties bring novel and unique capabilities and technologies to meet challenges
of drug discovery customers," said Pyare Khanna, CEO of DiscoveRx.

About DiscoveRx

Founded in 2000, DiscoveRx is a privately held, venture-backed company
headquartered in Fremont, California, with an additional office in Birmingham,
England. The Company pioneered the use of β-galactosidase enzyme fragment
complementation in biochemical and cell based assays for discovery research, and
holds extensive intellectual property in this area. DiscoveRx is dedicated to
the development and commercialization of innovative solutions to study GPCRs,
Kinases and other major drug target classes, and many of their innovative
products have been widely adopted in pharmaceutical and biotech drug screening
laboratories worldwide. The Company currently offers the broadest portfolio of
non-force coupled cell-based functional assays for known and orphan G-protein
coupled receptors. For more information on DiscoveRx products, please visit
www.discoverx.com

About BioFocus

BioFocus aims to expand its partners` drug pipelines by accelerating the
gene-to-drug candidate discovery process. This is achieved through a
comprehensive discovery platform, which includes target discovery in human
primary cells, focused as well as diverse compound libraries, in vitro and
cell-based screening, structural biology, medicinal chemistry, ADME/PK services,
supported by unique chemogenomic and informatics tools, and compound library
acquisition, storage and distribution services. As the service division of
Galapagos NV (Euronext:GLPG), BioFocus has over 250 employees in four countries
worldwide.

DiscoveRx Corporation
Sailaja Kuchibhatla, 510-979-1415 ext. 104
skuchibhatla@discoverx.com
www.discoverx.com
or
BioFocus
Will Spearing BSc, ACIM, +44 1799 533 528
Commercial Executive
Fax: +44 1799 531 495
www.biofocus.com

Copyright Business Wire 2009